| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.43 | 4e-17 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.36 | 2e-11 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.2 | 0.0004 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.18 | 0.002 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.1 | 0.06 |
| mRNA | Panobinostat | CCLE | pan-cancer | AAC | 0.084 | 0.09 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.092 | 0.09 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.091 | 0.1 |